Raymond James analyst Lawrence Keusch maintained a Buy rating on Hill-Rom (NYSE:HRC) on Monday, setting a price target of $113, which is approximately 12.09% above the present share price of $100.81.
Keusch expects Hill-Rom to post earnings per share (EPS) of $0.64 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Hill-Rom, with an average price target of $121.5.
The analysts price targets range from a high of $130 to a low of $113.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $705.3 million and a net profit of $81.6 million. The company's market cap is $6.69 billion.
According to TipRanks.com, Raymond James analyst Lawrence Keusch is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.7% and a 70.79% success rate.
Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following business segments: Patient Support System, Front Line Care, and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility, and clinical workflow solutions. The Front Line Care segment offers respiratory care products; and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products, and accessories. The company was founded by William A. Hillenbrand (NYSE:HI) on August 7, 1969 and is headquartered in Chicago, IL.